The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans

Journal of Infectious Diseases

Volumn 193, Issue 4, 2006, Pages 573-581

  Wright, Peter F ^a   Karron, Ruth A ^b   Madhi, Shabir A ^e   Treanor, John J ^f   King, James C ^c   O'Shea, Alice ^a   Ikizler, Mine R ^a   Zhu, Yuwei ^a   Collins, Peter L ^d   Cutland, Clare ^e   Randolph, Valerie B ^g   Deatly, Anne M ^g   Hackell, Jill G ^g   Gruber, William C ^g   Murphy, Brian R ^d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f UNIVERSITY OF ROCHESTER   (United States)

^g WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON; NONSTRUCTURAL PROTEIN 2; PLACEBO; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; MAJOR CLINICAL STUDY; NS2 GENE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VACCINATION; VACCINE PRODUCTION; VIRAL RESPIRATORY TRACT INFECTION; VIRUS ATTENUATION; VIRUS GENE; VIRUS IDENTIFICATION; VIRUS INFECTIVITY; VIRUS ISOLATION; VIRUS SHEDDING; VIRUS TITRATION; VIRUS VIRULENCE;

ADULT; CHILD; CHILD, PRESCHOOL; HUMANS; INTERFERONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VACCINATION; VIRAL NONSTRUCTURAL PROTEINS; VIRULENCE; VIRUS SHEDDING;

EID: 32044433987     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/499600     Document Type: Article

References (31)

1. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000; 137:865-70.
2. Fisher RG, Gruber WC, Edwards KM, et al. Twenty years ot outpatient respiratory syncytial virus infection: a framework for vaccine efficacy trials. Pediatrics 1997; 99:E7.
3. Mills J 5th, VanKirk JE, Wright PF, Chanock RM. Experimental respiratory syncytial virus infection of adults. J Immunol 1971; 107:123-30.
4. Friedewald WJ, Forsyth BR, Smith CB, Gharpure MA, Chanock RM. Low-temperature-grown RS virus in adult volunteers. JAMA 1968; 204: 690-4.
5. Crowe JE Ji, Bui PT, Davis AR, Hung PP, Chanock RM, Murphy BR. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 1995; 13:847-56.
6. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature sensitive, respiratory syncytial virus vaccine in infancy. J Infect Dis 2000; 182:1331-42.
7. Collins PL, Hill MG, Camargo E, Grosfeld H, Chanock RM, Murphy BR. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation tactor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability tor vaccine development. Proc Nat Acad Sci 1995; 92:11563-7.
8. Murphy BR, Collins PL. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J Clin Invest 2002; 110:21-7.
9. Collins PL, Chanock RM, Murphy BR. Respiratory syncytial virus. In: Knipe DM, Howley PM, eds. Fields virology. 4th ed. Vol. 1. Philadelphia: Lippincott Williams & Wilkins, 2001:1143-85.
10. Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live-attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005; 191:1093-104.
11. Young DF, Didcock FL, Goodbourn S, Randall RE. Paramyxoviridae use distinct virus-specific mechanisms to circumvent the interferon response. Virology 2000; 269:383-90.
12. Bessert B, Conzelmann KK. Respiratory syncytial virus (RSV) non-structural proteins as host range determinants: a chimeric bovine RSV with NS genes from human RSV is attenuated in interferon-competent bovine cells. J Virol 2002; 76:4287-93.
13. Sehender J, Bossert B, Buchholtz U, Conzelmann KK. Bovine respiratory syncytial virus nonstructural proteins NS1 and NS2 cooperatively antagonize alpha/beta interferon-induced antiviral response. J Virol 2000; 74:8234-42.
14. Spann KM, Tran KC, Chi B, Rabin RL, Collins PL. Suppression of the induction of alpha, beta, and gamma interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages. J Virol 2004; 78:4363-9.
15. Valarcher JF, Furze J, Wyld S, Cook R, Conzelmann KK, Taylor G. Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins. I Virol 2003; 77:8426-39.
16. Whitehead SS, Bukreyev A, Teng MN, et al. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol 1999; 73:3438-42.
17. Gonzalez IM, Karron RA, Eichelberger M, et al. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine 2000; 18:1763-72.
18. Teng MN, Whitehead SS, Bermingham A, et al. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol 2000; 74:9317-21.
19. Whitehead SS, Juhasz K, Firestone C-Y, Collins PL, Murphy BR. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol 1998; 72:4467-71.
20. Karron, RA, Wright PF, Crowe JE Jr, et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus (RSV) vaccines in chimpanzees, adults, infants, and children. J Infect Dis 1997; 176:1428-36.
21. Teng MN, Collins PL. Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein. J Virol 1999; 73:466-73.
22. Hu A, Colella M, Tamn JS, Rappaport R, Cheng SM. Simultaneous detection, subgrouping, and quantitation of respiratory syncytial virus A and B by real-time PCR. J Clin Microbiol 2003; 41:149-54.
23. Coates HV, Alling DW, Chanock RM. An antigenic analysis of respiratory syncytial virus isolates by a plaque neutralization test. Am J Epidemiol 1966; 83:299-313.
24. Boyce TG, Gruber WC, Coleman-Dockery SD, et al. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 1999; 18:82-8.
25. Kim HW, Arrobio JO, Pyles G, et al. Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus. Pediatrics 1971; 48:745-55.
26. Wright PF, Ikizler MR, Gonzales RA, Carroll KN, Johnson JE, Werkhaven JA. Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract. J Virol 2005; 79:8651-4.
27. Gharpure MA, Wright PF, Chanock RM. Temperature-sensitive mutants of respiratory syncytial virus. J Virol 1969; 3:414-21.
28. Falsey AR, Cunningham CK, Barker WH, et al. Respiratory syncytial virus and influenza A infections in hospitalized elderly. J Infect Dis 1995; 172:389-94.
29. Gruber WC, Hinson HP, Holland KL, Thompson JM, Reed GW, Wright PF. Comparative trial of large-particle aerosol and nose drop administration of live attenuated influenza vaccines. J Infect Dis 1993; 168: 1282-5.
30. Skiadopoulos MH, Surman S, Tatem JM, et al. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J Virol 1999; 73: 1374-81.
31. Spann KM, Tran KC, Collins PL. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-κB, and proinflammatory cytokines. J Virol 2005; 79: 5353-62.